$BHVN

Biohaven Ltd. (BHVN) shares fell after the FDA placed a partial clinical hold on its epilepsy drug candidate BHV-7000, introducing regulatory uncertainty and delaying progress. Investors also expressed concerns over the company's valuation and cash burn, intensifying selling pressure. Despite the setback, Biohaven has a $400 million funding deal and partnerships to extend its cash runway, but its stretched balance sheet and high cash burn remain risks.

Biohaven Ltd. (BHVN) shares surged after reporting positive Phase 3 trial results for troriluzole in treating Spinocerebellar Ataxia, meeting its main goal. The data may lead to an FDA application, potentially transforming the company into a commercial entity with a new revenue stream. Investors are optimistic but should monitor debt, cash burn, and regulatory risks.

Biohaven Ltd. (BHVN) shares rose 13% after licensing its epilepsy drug program to SK Biopharmaceuticals for up to $795M plus royalties. The deal includes $400M upfront, with Biohaven retaining royalties. SK aims to launch the drug in the U.S. by 2029. Biohaven plans to focus on other pipeline drugs, including obesity and immunology treatments. Raymond James cut its price target to $30 but maintains a 'Strong Buy' rating.

Biohaven's stock fell 13% after the FDA paused enrollment in pivotal trials for its epilepsy drug BHV-7000 due to rodent testing concerns. This is the second regulatory setback in a year. The company expects topline data from one trial later this year but may delay another. Biohaven believes the findings may not be relevant to human safety.

Biohaven (BHVN) halted a midstage study of its seizure drug, opakalim, after safety concerns. The FDA requires further assessment of potential human toxicity from a metabolite. This caused BHVN stock to drop, potentially benefiting rival Xenon.

Biohaven Pharmaceutical (BHVN) shares dropped 12% in pre-market trading after the FDA placed a partial clinical hold on its lead epilepsy drug, BHV-7000, requiring additional studies. The hold delays new patient enrollment but allows existing patients to continue treatment. The company also filed a Form 8-K with the SEC, adding to investor uncertainty. The S&P 500, Dow Jones, and Nasdaq showed minimal movement, indicating the selloff is company-specific.

Biohaven Ltd. (BHVN) shares rose 7% after hitting enrollment milestones in epilepsy and obesity trials, with data readouts expected in H2 2026. The company also began a late-stage trial for Graves' disease. BHVN has gained 47% year-to-date, with retail sentiment turning neutral.

Biohaven Pharmaceutical (BHVN) shares fell 1.9% premarket after RBC Capital downgraded the stock to Sector Perform, cutting its price target to $19 from $23. The downgrade was based on valuation following a 100% rise from 2023 lows. RBC also noted limited patient data for Biohaven's Opakalim epilepsy program. The company recently received $400M from a licensing deal with SK Biopharmaceuticals.

Biohaven (BHVN) and SK Biopharmaceuticals agreed to a $795M deal for Biohaven's epilepsy drug opakalim, with Biohaven receiving $400M upfront. Opakalim showed promising results in epilepsy studies, and the deal includes milestone payments and royalties. Biohaven will use the funds to support its pipeline, including other drug candidates. According to Biohaven, the deal allows it to monetize its pipeline through partnerships rather than public markets.

Biohaven (BHVN) announced a global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, including opakalim for focal epilepsy. The stock has seen significant gains, with a 90-day return of 52.12% and a year-to-date return of 42.16%. However, it trades at a high price-to-book ratio of 190.4x, raising valuation concerns. Analysts expect Biohaven to remain unprofitable over the next 3 years, with no meaningful revenue and a net loss of $586.841m.